Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Many variables impact the Alpha-1 Antitrypsin Deficiency (AATD) therapies market. A hereditary illness called Alpha-1 Antitrypsin Deficiency (AATD) causes protein deficiency, which damages the lungs and liver. AATD research and medication development transform the therapy market.
Alpha-1 Antitrypsin Deficiency (AATD) influences the market since it's global. Effective therapies are required as more individuals learn about this uncommon genetic condition and find more instances. Healthcare workers and drug companies are investing more in research into new therapies because more people know about them.
Improvements in diagnostic and treatment technology affect the industry. Advanced genetic testing and diagnostic technologies may discover AATD early, allowing rapid intervention. Gene therapy and precision medicine are also changing AATD treatment.
New AATD drugs are being developed by pharmaceutical companies. The market has more unique therapeutic options, including gene-based therapies and drugs that improve particular characteristics. These advances improve treatment and tackle AATD's genetic causes.
The regulatory environment strongly impacts AATD therapeutic market dynamics. Novel medicines are controlled to make sure they are safe and effective, which takes longer than getting a drug license. Partnerships between governing authorities and the pharmaceutical business are needed for drug research and approval to go smoothly.
There is more competition among drug companies to get a piece of the AATD treatment business. The challenge is pushing researchers and developers to come up with new treatments. Differentiation is important for market players in the AATD treatment business to make their products look like the best.
AATD drugs must be easy for patients to get in order for the market to work. Price problems could make it harder for people to use these drugs. Pharmaceutical firms and healthcare providers are developing long-term pricing and payment agreements to help people acquire their medications.
The way AATD treatment is developed is affected by how universities, drug companies, and study groups work together. Collaborations accelerate medicine development by sharing resources, expertise, and funds. These agreements advance AATD research and therapy development.
The AATD treatment market is global. Global factors including healthcare infrastructure expansion, illness patterns, and economics affect market dynamics. To navigate the global AATD treatment market, participants must understand and adapt to these tendencies.
Technology research and development should boost the AATD therapy industry. However, legislative restrictions, high development costs, and public ignorance persist. Alpha-1 Antitrypsin Deficiency sufferers must overcome several issues to succeed.
Alpha 1 Antitrypsin Deficiency Treatment Market Highlights:
Alpha-1 Antitrypsin Deficiency Treatment Market Overview
Alpha-1 Antitrypsin Deficiency Treatment Market Size was valued at USD 3.12 Billion in 2023. The Global Alpha-1 Antitrypsin Deficiency Treatment industry is projected to grow from USD 3.52 Billion in 2024 to USD 9.28 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.23% during the forecast period (2024 - 2032).
Growing product pipeline for alpha-1 antitrypsin drugs and rising prevalence of alpha-1 antitrypsin deficiency are set to drive the market growth for alpha-1 antitrypsin deficiency treatment. Approximately 100,000 people in the US are known to suffer from alpha-1 antitrypsin deficiency. Rising awareness regarding the alpha-1 antitrypsin deficiency is expected to drive the market growth of the alpha-1 antitrypsin deficiency treatment.
Strategic mergers & acquisitions are also projected to boost alpha-1 antitrypsin deficiency treatment market growth with companies looking to strengthen their market positions, expand their product portfolios, and improve their brand images. For instance, on 3rd September 2019, Kamada Pharmaceuticals signed an agreement with Takeda Pharmaceutical Ltd for supply and distribution of Glassia, which is an alpha-1 proteinase inhibitor used for the treatment of alpha-1 antitrypsin deficiency.
High unmet medical needs in developing economies are directly providing lucrative opportunities for the alpha-1 antitrypsin deficiency treatment market growth.
Market Influencers
The rising number of product approvals. For instance, in September 2017, Grifols S.A. received a biologics license approval for Alpha-1 Proteinase Inhibitor to add a new liquid formulation to the currently licensed Prolastin C.
Market Drivers
- Increasing prevalence of alpha-1 antitrypsin deficiency. Alpha-1 antitrypsin deficiency or AATD is a genetic disease that may cause severe lung or liver disfunction. The prevalence of alpha-1 antitrypsin deficiency is increasing, which is resulting in market growth. 1 in 1500 to 3500 Europeans are affected by AATD. Since the prevalence of AATD is increasing, the demand for treatment of AATD is also increasing, which is resulting in the positive market growth of the alpha-1 antitrypsin deficiency treatment.
- Growing product pipeline for alpha-1 antitrypsin deficiency treatment drugs
- Rising awareness regarding alpha-1 antitrypsin deficiency
- High unmet medical needs in developing economies
- Increasing R&D expenditure by key players to develop innovative treatment options for AATD
Market Restraints
- Stringent government regulatory policies
- High cost of drugs
Alpha-1 Antitrypsin Deficiency Treatment Market Segmentation Insights
Alpha-1 Antitrypsin Deficiency Treatment Drugs Insights
- Alpha-1 Proteinase Inhibitor: This drug type is expected to hold the largest market share. In April 2019, CSL Behring received FDA approval for Zemaira, which is alpha-1 proteinase inhibitor. So, the rising number of product approvals is expected to drive the alpha-1 antitrypsin deficiency treatment market growth.
- Bronchodilators: Used for prevention from upper respiratory tract infections.
- Steroids: Consists of corticosteroids used for the treatment of COPD associated with AATD.
- Others: Consists of oxygen therapy, antibiotics, and other drugs used for the treatment of complications associated with AATD, such as jaundiced skin, breathing problems, etc.
Alpha-1 Antitrypsin Deficiency Treatment Route of Administration Insights
- Oral: This route of administration is expected to hold the largest alpha-1 antitrypsin deficiency treatment market share due to its high usage.
- Intravenous: This drug type is expected to grow at the fastest rate owing to the ease of administration.
- Inhalation: This route of administration is mainly used for administration of corticosteroids and drugs for the treatment of breathing disorders associated with AATD.
- Others: Consists of subcutaneous and intramuscular routes of administration.
Alpha-1 Antitrypsin Deficiency Treatment Distribution Channel Insights
- Hospital Pharmacy: The segment holds the largest market size as the treatment is mostly carried out in hospitals.
- Retail Pharmacy: They provide prescriptions that are intended to be used at home.
- Online Stores: Fastest growing segment owing to the increasing number of online pharmacy stores.
Alpha-1 Antitrypsin Deficiency Treatment Regional Insights
- Americas: The largest regional market. The high patient population suffering from alpha-1 antitrypsin deficiency is expected to drive the market growth of alpha-1 antitrypsin deficiency treatment. Approximately 1 in 2,500 Americans suffer from the disease. This serves to drive the market growth of the alpha-1 antitrypsin deficiency treatment in the region.
- Europe: Europe has some of the best healthcare services in the world. Increasing prevalence and the developed healthcare industry are driving the alpha-1 antitrypsin deficiency treatment market growth.
- Asia-Pacific: The fastest-growing regional market for alpha-1 antitrypsin deficiency treatment, Asia-Pacific has the world’s largest population and fast-developing healthcare industry which is anticipated to drive the market growth.
- Middle East & Africa: The market growth of alpha-1 antitrypsin deficiency treatment is attributed to the developing healthcare industry in regions such as Saudi Arabia, Oman, and Qatar.
Key Players
- Kamada Pharmaceuticals (Israel)
- CSL Behring LLC (US)
- Grifols, S.A. (Spain)
- Takeda Pharmaceutical Company Limited (Japan)
- GlaxoSmithKline plc (UK)
- Boehringer Ingelheim GmbH (Germany)
- AstraZeneca (UK)
- Vectura Group plc (UK)
- Pfizer Inc. (US)
- Mylan Inc. (US)
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
